In the fifth part of our FDA: Drug & Device Team’s series on biological products regulation, we discuss key considerations for biologics license applications (BLAs) and the Food and Drug ...
Expanded indication would cover patients 12 years of age or younger, a population that comprises approximately one in three patients treated for hemophilia B in the United States Toronto, Ontario and ...
Mumbai, May 24 (IANS) Drug major Sun Pharmaceutical Industries Ltd on Wednesday said the US Food and Drug Administration (USFDA) has accepted its Biological License Application (BLA) for tildrakizumab ...
On April 3, 2023, Vertex Pharmaceuticals and CRISPR Therapeutics announced that they submitted Biological License Applications (BLAs) for an investigational treatment using exagamglogene autotemcel ...